Joseph Saddik | Pharmacology, Toxicology and Pharmaceutical Science | Best Innovation Award

Published on by Academic Excellence

Best Innovation Award

Joseph Saddik
Pfizer,United States

Joseph Saddik
Affiliation Pfizer
Country United States
Scopus ID 57223125865
Documents 2
Citations 25
h-index 2
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event International Academic Excellence Awards
ORCID 0000-0003-1490-9517

Joseph Saddik is identified with research in pharmaceutical science, particularly powder rheology, tablet compaction, compactability, and manufacturing-related performance of acetaminophen tablets. His listed publications address formulation and processing variables associated with tablet manufacture and the prediction or mitigation of sticking during compression. [1][2]

Abstract

The research record associated with Joseph Saddik centers on pharmaceutical powder processing and tablet manufacturing. The documented work examines powder rheology, tablet compactability, and sticking behavior, with particular attention to formulation factors, glidant selection, punch-metal effects, and multivariate analytical approaches. These topics are relevant to pharmaceutical manufacturing because powder flow and compaction characteristics can influence tablet quality and process performance. [2][3]

Keywords

Pharmaceutical science; powder rheology; tablet compression; acetaminophen; compactability; sticking; glidants; punch metals; multivariate analysis.

Introduction

Tablet manufacture involves interconnected material and process variables. Acetaminophen is frequently used as a model active pharmaceutical ingredient for studying compression behavior because formulation and processing conditions can affect compaction and manufacturing outcomes. Research examining these relationships can support improved understanding of tablet formation and compression-related defects. [2]

Research Profile

The supplied researcher record lists Pfizer as the institutional affiliation and identifies Pharmacology, Toxicology and Pharmaceutical Science as the subject area. The supplied bibliographic information records two documents, 25 citations, and an h-index of 2, alongside Scopus author identifier 57223125865. These metrics are bibliographic indicators and should be interpreted in relation to database coverage and publication history. [1]

Research Contributions

The documented studies contribute to the characterization of pharmaceutical powders and compressed tablets. One study evaluates powder rheology as a potential predictor of tablet sticking, while another investigates manufacturing and formulation factors affecting acetaminophen compactability. The 2026 study further develops this research direction by examining glidant type and punch-metal selection in high-drug-load acetaminophen tablets. [2][3][4]

Publications

  • Predicting and Mitigating Sticking in High-Drug-Load Acetaminophen Tablets Using a Powder Rheology-Compression Approach: Evaluation of Glidant Type and Punch Metal Selection. Powders, 2026. [4]
  • Investigating the Impact of Manufacturing and Formulation Factors on the Compactability of Acetaminophen Tablets Using Heckel and Multivariate Analysis. International Journal of Pharmaceutical Sciences and Research, 2021. [2]
  • Evaluation of powder rheology as a potential tool to predict tablet sticking. Powder Technology, 2021. [3]

Research Impact

The reported citation count indicates that the research has received citations within the indexed scholarly literature. Its thematic focus also connects fundamental powder characterization with practical tablet-manufacturing concerns, including sticking and compactability. Such work may be relevant to formulation development and process understanding, although citation metrics alone do not establish practical or clinical impact. [1]

Award Suitability

For consideration in the International Academic Excellence Awards, the documented publication record provides identifiable evidence of research activity in pharmaceutical manufacturing and powder science. The studies present a coherent research theme spanning rheological characterization, compaction analysis, and mitigation of tablet sticking. Award decisions, however, remain subject to the criteria, documentation, and assessment procedures established by the awarding organization. [5]

Conclusion

Joseph Saddik’s documented research is focused on technically specific problems in pharmaceutical tablet manufacture, particularly powder rheology, compactability, and sticking. The available publications demonstrate continuity across these subjects and provide a scholarly basis for describing his research profile within pharmaceutical science. [2][3][4]

References

  1. Elsevier. (n.d.). Scopus author details: Joseph Saddik, Author ID 57223125865. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57223125865
  2. International Journal of Pharmaceutical Sciences and Research. (2021). Investigating the Impact of Manufacturing and Formulation Factors on the Compactability of Acetaminophen Tablets Using Heckel and Multivariate Analysis. DOI: 10.13040/ijpsr.0975-8232.12(2).1240-50
  3. Powder Technology. (2021). Evaluation of powder rheology as a potential tool to predict tablet sticking. DOI: 10.1016/j.powtec.2021.03.062
  4. MDPI. (2026). Predicting and Mitigating Sticking in High-Drug-Load Acetaminophen Tablets Using a Powder Rheology-Compression Approach: Evaluation of Glidant Type and Punch Metal Selection. Powders, 5(3), 31.
    https://doi.org/10.3390/powders5030031
  5. International Academic Excellence Awards. (n.d.). Award program information.
    https://academicexcellenceawards.com/
  6. ORCID. (n.d.). Joseph Saddik, ORCID record 0000-0003-1490-9517.
    https://orcid.org/0000-0003-1490-9517

Karthikeyan Kesavan | Pharmacology | Best Researcher Award

Published on by Academic Excellence

Assoc. Prof. Dr. Karthikeyan Kesavan | Pharmacology | Best Researcher Award

Assoc. Prof. Dr. Karthikeyan Kesavan | Pharmacology | Department of Pharmacy, Guru Ghasidas University | India

Dr. Karthikeyan Kesavan is an accomplished academic and researcher serving as an Associate Professor in the Department of Pharmacy at Guru Ghasidas Vishwavidyalaya, Bilaspur. With a Ph.D. in Pharmaceutics from IIT-BHU and postdoctoral research experience at the University of Iowa under the DBT-GETin Fellowship, he has established himself as an expert in nanopharmaceuticals and ocular drug delivery. His research integrates nanotechnology with pharmaceutics to design innovative formulations for treating complex ocular and infectious diseases. Dr. Kesavan has guided Ph.D. and postgraduate scholars, published extensively in high-impact journals, authored influential book chapters, and holds multiple patents in novel drug delivery technologies. His consultancy projects also extend expertise in nanoformulations of natural metabolites for managing ocular diseases. With an H-index of 16 and growing international collaborations, Dr. Kesavan continues to bridge cutting-edge research with practical healthcare applications, contributing significantly to the advancement of pharmacology and pharmaceutical sciences.

Author Profiles

Orcid | Google Scholar

Education 

Dr. Kesavan’s educational journey reflects excellence and dedication to pharmaceutical sciences. He earned his Bachelor of Pharmacy degree, which laid the foundation for his research interests, before pursuing a Master of Pharmacy (M. Pharm) in Pharmaceutics from Bharathidasan University. His academic passion led him to the prestigious Indian Institute of Technology (BHU), Varanasi, where he obtained his Ph.D. in Pharmaceutics, specializing in novel drug delivery systems. To further strengthen his expertise, he completed postdoctoral research at the University of Iowa, USA, under the distinguished DBT-GETin Fellowship, where he gained advanced experience in nanotechnology-based ocular drug delivery. This exposure enhanced his global outlook and scientific rigor, allowing him to integrate diverse approaches into his work. His education uniquely positioned him to contribute to both academic and industry-level pharmaceutical innovations. Today, his academic background continues to influence his impactful research in nanopharmaceuticals, ocular therapeutics, and gene delivery strategies.

Experience

Dr. Kesavan has more than a decade of experience in academia, research, and international collaboration. As an Associate Professor at Guru Ghasidas Vishwavidyalaya, he has played a pivotal role in advancing pharmaceutics education and research. His career includes mentoring doctoral and postgraduate students, designing advanced curricula, and fostering multidisciplinary projects. His consultancy experience extends to developing nanoformulations from medicinal plant metabolites for ocular disease management, bridging academia and applied science. Internationally, his postdoctoral research at the University of Iowa refined his expertise in nanocarrier-mediated gene therapy and non-viral delivery systems. Dr. Kesavan has completed projects funded by UGC, including innovative work on chitosan-coated cationic nanoemulsions for ocular delivery. His professional contributions encompass guiding clinical relevance, managing funded projects, publishing in SCI-indexed journals, authoring influential book chapters, and securing multiple patents. His diverse roles highlight his leadership in pharmacological innovation and his ability to translate research into practical applications.

Awards & Honors 

Throughout his career, Dr. Kesavan has earned significant recognition for his contributions to pharmaceutics and drug delivery research. His selection for the prestigious DBT-GETin Fellowship enabled him to conduct postdoctoral research at the University of Iowa, expanding his international collaborations. He has been awarded UGC-BSR startup grants for innovative work in ocular nanopharmaceuticals, particularly chitosan-coated cationic nanoemulsions. His impactful research has led to multiple patent awards, including recognition for hybrid hydrogel systems and IoT-based health monitoring devices, demonstrating his interdisciplinary innovation. Beyond patents, his publications in high-impact journals and contributions to specialized book chapters highlight his scientific leadership. His role in guiding research scholars and his consultancy services further showcase his dedication to advancing pharmaceutical sciences. These honors not only validate his scientific excellence but also underscore his commitment to pioneering new frontiers in pharmacology and translating research into therapeutic solutions.

Research Focus

Dr. Kesavan’s research focus lies at the intersection of nanotechnology and pharmacology, with a special emphasis on ocular drug delivery systems. His investigations aim to overcome biological barriers by developing innovative nanocarriers, such as nanoemulsions, micelles, and nanocapsules, for improved treatment of eye diseases like glaucoma, uveitis, bacterial keratitis, and fungal infections. His work also explores gene therapy approaches using non-viral vectors for safer and more effective management of ocular disorders. In addition, his patents reflect his expertise in designing mucoadhesive, biocompatible systems that enhance therapeutic efficacy while reducing side effects. Expanding beyond ocular pharmacology, he has also contributed to cancer therapy and infectious disease research through nanocarrier-based formulations. By integrating pharmaceutical sciences with biotechnology and engineering, Dr. Kesavan’s research demonstrates translational value, bridging laboratory discoveries with clinical applications. His focus continues to advance the field of nanopharmaceuticals, ensuring patient-centered, innovative, and sustainable therapeutic solutions.

Publications

    • Healing efficiency of nystatin-loaded chitosan-guar gum-based nanocapsules in experimental fungal keratitis.

    • Tear-Driven Phase Transition Microemulsion for Ocular Delivery of Dexamethasone in Uveitis.

    • Cationic microemulsion of voriconazole for fungal keratitis treatment: in vitro and in vivo evaluation.

    • TPGS-Chitosan Conjugated Mucoadhesive Micelles of Brinzolamide for Glaucoma Therapy.

    • Cationic Chitosan/Pectin Nanocapsules of Moxifloxacin for Bacterial Keratitis Management.

    • Cationic Polyelectrolyte Nanocapsules of Moxifloxacin for Microbial Keratitis Therapy.

    • Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy.

    • Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for glaucoma therapy.

    • Positively Charged TPGS-Chitosan Nanocapsules as Non-Viral Vector for Glaucoma Gene Therapy.

    • Topical Ocular Delivery of Nanocarriers: A Feasible Choice for Glaucoma Management.

    • Ocular SMEDDS of Prednisolone for Improved Uveitis Therapy .

    • Tamoxifen citrate loaded chitosan-gellan nanocapsules for breast cancer therapy.

    • Phase Transition W/O Microemulsions for Antibacterial Activity in Bacterial Keratitis.

    • Chitosan-Coated Microemulsions for Enhanced Dermal Clotrimazole Delivery.

Conclusion

Dr. Karthikeyan Kesavan exemplifies excellence in pharmacology through his pioneering research in nanopharmaceuticals, ocular drug delivery, and innovative therapeutic approaches. With a strong educational foundation, impactful teaching experience, and international collaborations, he has established himself as a leader in pharmaceutical research. His extensive publications, patents, and consultancy work highlight his contributions to both academic and industrial advancements. Dr. Kesavan’s dedication to addressing unmet medical needs through nanotechnology-driven solutions continues to shape the future of pharmacology, making him a highly deserving candidate for recognition in the field.